@article{Chen2025, 
author = {Tingting Chen and Lifei Liang and Siyue Chen and Qing Xu and Xiaoyu Li and Ming Xu and Ruiming Rong and Tongyu Zhu and Cheng Yang},
title = {Basiliximab for the Treatment of Acute T‐Cell Mediated Rejection After Kidney Transplantation: Case Series and Preliminary Experience},
year = {2025},
journal = {Organ Medicine},
volume = {2},
number = {1},
pages = {31-40},
keywords = {basiliximab, IL‐2 receptor antagonist, kidney transplantation, T cell‐mediated rejection},
url = {https://www.sciopen.com/article/10.1002/orm2.70002},
doi = {10.1002/orm2.70002},
abstract = {BackgroundThe study aims to evaluate the preliminary efficacy and safety of basiliximab in treating acute T cell‐mediated rejection (TCMR) after kidney transplantation, particularly in patients with poor responses to standard treatments.MethodsWe conducted a retrospective case series study involving eight kidney transplant recipients at Zhongshan Hospital, Fudan University, who received basiliximab for anti‐TCMR treatment. Baseline characteristics, immunosuppression management data, and treatment outcomes were collected.ResultsAmong the eight patients, two had biopsy‐proven TCMR. Elevated serum soluble IL‐2R (sIL‐2R) level were detected in all patients before basiliximab treatment. Following basiliximab therapy, all patients exhibited a rapid decrease in sIL‐2R levels, and most cases showed a general downward trend in serum creatinine levels. Although two patients developed pulmonary infections posttreatment, no clear correlation was found between the use of basiliximab and infections. No other new infections or adverse reactions were reported.ConclusionsBasiliximab therapy demonstrates efficacy and good tolerance in patients with TCMR.}
}